You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
*本文来源于21世纪经济报道对安斯泰来大中华商业总经理滨口洋先生的独家专访，全文如下： 21世纪经济报道记者 朱萍 北京报道...
安斯泰来MOONLIGHT 1TM临床研究目的为评估每日一次服用30mg Fezolinetant 的疗效...
Read more about 安斯泰来宣布非激素类药物Fezolinetant治疗亚洲女性绝经相关血管舒缩症Ⅲ期临床试验12周阶段性结果
乐城作为中国特色自由贸易港的先驱“试验田”，是国际创新药械更早惠及中国患者的窗口，与安斯泰来的愿景“立志处于不断变化的医疗行业的最
近日，安斯泰来宣布向四家世界慈善组织提供资金支持，这些组织一直致力于为迫切需要医疗救助的患者提供服务。通过该项目，安斯泰来继续加大
Follow China news
